NASDAQ:BIIB - Biogen Stock Price, Forecast & News

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen declared that its Board of Directors has approved a stock buyback program on Monday, December 23rd 2019, which allows the company to buyback $5,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company's management believes its stock is undervalued.

Biogen Inc (NASDAQ:BIIB) posted its quarterly earnings data on Thursday, January, 30th. The biotechnology company reported $8.34 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $8.02 by $0.32. The biotechnology company earned $3.67 billion during the quarter, compared to analysts' expectations of $3.51 billion. Biogen's revenue for the quarter was up 4.1% compared to the same quarter last year. During the same quarter last year, the company earned $6.99 earnings per share. View Biogen's Earnings History.

Biogen is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Biogen.

Biogen issued an update on its FY20 earnings guidance on Thursday, January, 30th. The company provided earnings per share guidance of $31.50-33.50 for the period, compared to the Thomson Reuters consensus estimate of $31.98. The company issued revenue guidance of ~$14.0-14.3 billion, compared to the consensus revenue estimate of $13.85 billion.

34 Wall Street analysts have issued twelve-month price targets for Biogen's shares. Their forecasts range from $230.00 to $410.00. On average, they anticipate Biogen's stock price to reach $316.69 in the next twelve months. This suggests that the stock has a possible downside of 4.9%. View Analyst Price Targets for Biogen.

34 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 3 sell ratings, 20 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Biogen.

Headlines about BIIB stock have trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Biogen earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View News Stories for Biogen.

Biogen saw a decline in short interest in January. As of January 31st, there was short interest totalling 3,600,000 shares, a decline of 16.9% from the January 15th total of 4,330,000 shares. Based on an average daily volume of 1,790,000 shares, the days-to-cover ratio is presently 2.0 days. Approximately 2.0% of the shares of the company are sold short. View Biogen's Current Options Chain.

Some companies that are related to Biogen include Amgen (AMGN), Celgene (CELG), Alexion Pharmaceuticals (ALXN), Alnylam Pharmaceuticals (ALNY), Arena Pharmaceuticals (ARNA), ArQule (ARQL), Achillion Pharmaceuticals (ACHN), Osiris Therapeutics (OSIR), SIGA Technologies (SIGA), AMAG Pharmaceuticals (AMAG), BioTime (BTX), AVEO Pharmaceuticals (AVEO), Vical (VICL), ImmunoCellular Therapeutics (IMUC) and Achieve Life Sciences (ACHV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Netflix (NFLX), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Celgene (CELG), Tesla (TSLA), Amgen (AMGN), Micron Technology (MU), Walt Disney (DIS) and Intel (INTC).

Biogen's stock is owned by many different of retail and institutional investors. Top institutional investors include State Street Corp (4.56%), Renaissance Technologies LLC (2.63%), AQR Capital Management LLC (1.51%), Bank of New York Mellon Corp (1.22%), FMR LLC (0.81%) and Boston Partners (0.78%). Company insiders that own Biogen stock include Alexander J Denner, Alfred Sandrock, Brian S Posner, Michael D Ehlers, Michel Vounatsos and Robert W Pangia. View Institutional Ownership Trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Jackson Square Partners LLC, AQR Capital Management LLC, FMR LLC, State Street Corp, Assenagon Asset Management S.A., Massachusetts Financial Services Co. MA, Bank of Montreal Can and Virginia Retirement Systems ET AL. Company insiders that have sold Biogen company stock in the last year include Brian S Posner and Robert W Pangia. View Insider Buying and Selling for Biogen.

BIIB stock was bought by a variety of institutional investors in the last quarter, including Amundi Pioneer Asset Management Inc., Renaissance Technologies LLC, Los Angeles Capital Management & Equity Research Inc., Bank of New York Mellon Corp, Fred Alger Management LLC, First Trust Advisors LP, Samlyn Capital LLC and Marshall Wace North America L.P.. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $333.00.